Switching from Tysabri to moderate-efficacy DMTs linked to worse outcomes in MS Published: 26 February 2021 Switching from Tysabri (natalizumab) to moderate-efficacy disease-modifying therapies (DMTs) puts patients with multiple sclerosis (MS) at a higher risk of further disease activity and disability progression compared with those who switch to a high-efficacy